Shares of Imprimis Pharmaceuticals have more than doubled year-to-date because of strong interest in its 'dropless' cataract surgery, said the company's CEO Mark Baum. Baum added that this eye surgery will be a game changer for patients and tremendous savings for Medicare. He said Imprimis has also benefited from the effectiveness of the company's unique commercialization model. Baum said Imprimis intends to expand on its success in ophthalmology by adding a second business unit in urology during 2015 with another injectable drug. Finally, he said demography is on his side since his projects are in line with the aging of America.
Stock quotes in this video: